CAS NO: | 1338247-35-0 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | BMS-5 (LIMKi 3) is a potentLIMKinhibitor withIC50s of 7 nM and 8 nM forLIMK1andLIMK2, respectively. | ||||||||||||||||
IC50& Target[1] |
| ||||||||||||||||
体外研究 (In Vitro) | BMS-5 (LIMKi 3) inhibits cofilin-Ser3 phosphorylation in a dose-dependent manner inNf2ΔEx2mouse Schwann cells (MSCs) with an IC50of ~2 μM. BMS-5 (LIMKi 3) reducesNf2ΔEx2MSC viability in a dose-dependent manner with an IC50of 3.9 μM, but does not significantly reduce the viability of controlNf2flox2/flox2MSCs at equivalent BMS-5 concentrations. At 10 μM BMS-5,Nf2ΔEx2MSC viability is 40% compared to 83% for controls[2]. | ||||||||||||||||
体内研究 (In Vivo) | BMS-5 (LIMKi 3) (20 or 200 μM/side) is bilaterally infused into the hippocampus of rats immediately after contextual fear conditioning training. Rats are tested for memory consolidation 48 h after fear conditioning. Post hoc analysis shows that the group treated with 200 μM BMS-5 express lower freezing levels compared to the 20 μM and vehicle groups (P<0.01)[3]. | ||||||||||||||||
分子量 | 431.29 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C17H14Cl2F2N4OS | ||||||||||||||||
CAS 号 | 1338247-35-0 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 34 mg/mL(78.83 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|